CERO THERAPEUTICS HOLDINGS, INC.
CERO CEROWCIK 0001870404
Revenue (TTM)
—
Q1 May 2026
Net Income (TTM)
−$21.27M
−157.6% YoY
Q1 May 2026
EPS Diluted (TTM)
−$102.83
+81.5% YoY
Q1 May 2026
Gross Margin
—
Q1 May 2026
Operating Margin
—
Q1 May 2026
Net Margin
—
Q1 May 2026
Free Cash Flow (TTM)
—
Q1 May 2026
Cash
$1.9M
Q1 May 2026
Total Debt
$136.77K
Q1 May 2026
Shares Outstanding
45.11M sh
Q1 May 2026
Revenue & Net Income
EPS (Diluted)
Cash Flow
Revenue Growth (YoY)
No data available for this metric.